Bausch Health cut to hold by Jefferies over B+L update
Jefferies has downgraded Bausch Health (NYSE:BHC) to hold from buy, citing news that a possible sale of its Bausch+Lomb (NYSE:BLCO) unit to a private equity group has fallen through. "While ownership ...
Eli Lilly Stock Rises After Profit, Outlook Top Expectations
Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...
Rosenblatt raises ARM Holdings stock target to $225, keeps Buy rating
Rosenblatt Securities adjusted its outlook for Arm Holdings (NASDAQ:ARM), increasing the price target on the company's stock to $225 from the previous $180. The firm has also reaffirmed its Buy rating ...
Jefferies Keeps Their Buy Rating on Life360 Shs Chess Depository Interests Repr 3 Sh (LIFX)
In a report released today, Wei Sim from Jefferies maintained a Buy rating on Life360 Shs Chess Depository Interests Repr 3 Sh (LIFX – Research ...
Jefferies Sticks to Its Hold Rating for REA Group Ltd (RPGRF)
In a report released today, Roger Samuel from Jefferies maintained a Hold rating on REA Group Ltd (RPGRF – Research Report), with a price ...
The Financial Express19h
JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…
Jefferies maintains a Buy rating on JB Pharma citing strong CDMO growth potential and a 34% upside. Know more about it.
Jarden poaches from Jefferies for new head of financials research
Wilson will be based in Melbourne and joins Jarden after its equity capital markets team ended 2024 on the No.5 spot on the ...